Last reviewed · How we verify

R-CHOP with doxorubicin

Fondazione Italiana Linfomi - ETS · Phase 2 active Small molecule

R-CHOP with doxorubicin is a Monoclonal antibody and anthracycline antibiotic Small molecule drug developed by Fondazione Italiana Linfomi - ETS. It is currently in Phase 2 development for Non-Hodgkin lymphoma. Also known as: R-CHOP with doxorubicin analogue, R-COMP.

Rituximab targets CD20 on B cells, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II.

Rituximab targets CD20 on B cells, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. Used for Non-Hodgkin lymphoma.

At a glance

Generic nameR-CHOP with doxorubicin
Also known asR-CHOP with doxorubicin analogue, R-COMP
SponsorFondazione Italiana Linfomi - ETS
Drug classMonoclonal antibody and anthracycline antibiotic
TargetCD20
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Rituximab is a monoclonal antibody that induces direct and antibody-dependent cellular cytotoxicity against B cells expressing CD20. Doxorubicin is a chemotherapeutic agent that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about R-CHOP with doxorubicin

What is R-CHOP with doxorubicin?

R-CHOP with doxorubicin is a Monoclonal antibody and anthracycline antibiotic drug developed by Fondazione Italiana Linfomi - ETS, indicated for Non-Hodgkin lymphoma.

How does R-CHOP with doxorubicin work?

Rituximab targets CD20 on B cells, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II.

What is R-CHOP with doxorubicin used for?

R-CHOP with doxorubicin is indicated for Non-Hodgkin lymphoma.

Who makes R-CHOP with doxorubicin?

R-CHOP with doxorubicin is developed by Fondazione Italiana Linfomi - ETS (see full Fondazione Italiana Linfomi - ETS pipeline at /company/fondazione-italiana-linfomi-ets).

Is R-CHOP with doxorubicin also known as anything else?

R-CHOP with doxorubicin is also known as R-CHOP with doxorubicin analogue, R-COMP.

What drug class is R-CHOP with doxorubicin in?

R-CHOP with doxorubicin belongs to the Monoclonal antibody and anthracycline antibiotic class. See all Monoclonal antibody and anthracycline antibiotic drugs at /class/monoclonal-antibody-and-anthracycline-antibiotic.

What development phase is R-CHOP with doxorubicin in?

R-CHOP with doxorubicin is in Phase 2.

What are the side effects of R-CHOP with doxorubicin?

Common side effects of R-CHOP with doxorubicin include Neutropenia, Anemia, Thrombocytopenia, Infection, Cardiotoxicity.

What does R-CHOP with doxorubicin target?

R-CHOP with doxorubicin targets CD20 and is a Monoclonal antibody and anthracycline antibiotic.

Related